Market Place
Sourcing Support
Rick R. Suarez Appointed US President Of US Biopharma Unit
09 Jan 2026 //
PHARMIWEB
AZ Touts Phase 3 Lupus Win For Subcutaneous Saphnelo
06 Jan 2026 //
FIERCE PHARMA
Astrazeneca Elevates Vikram Chand As SVP, Head Of R&D For Japan
04 Jan 2026 //
INDPHARMAPOST
Astrazeneca`s Ph. 3 Cancer Fail Is Latest Blow To ATR Inhibitors
24 Dec 2025 //
FIERCE BIOTECH
FDA Grants ENHERTU BTD for HER2+ Early Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
FDA OKs ENHERTU Breakthrough Designation for HER2+ Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
Jacobio Enter Global Exclusive License Agreement with AstraZeneca
21 Dec 2025 //
PR NEWSWIRE
AZ To Pull Bleeding Reversal Agent After FDA Flags Risk Imbalance
19 Dec 2025 //
FIERCE PHARMA
Niowave Expands Supply Deal With Astrazeneca For Actinium-225
18 Dec 2025 //
PR NEWSWIRE
EU Validates DATROWAY for First-Line Metastatic Treatment
18 Dec 2025 //
BUSINESSWIRE
Astrazeneca India Granted CDSCO Approval For Datopotamab
18 Dec 2025 //
INDPHARMAPOST
Compugen Monetizes AstraZeneca Rilvegostomig Royalties Up to $90M
17 Dec 2025 //
PR NEWSWIRE
GSK`s Saphnelo EU Approved For Self-Administered Lupus Pen
16 Dec 2025 //
PHARMIWEB
FDA Approves Roche`s ENHERTU for HER2+ Metastatic Breast Cancer
16 Dec 2025 //
PR NEWSWIRE
FDA Approves AZ/Daiichi`s Enhertu in 1st-Line Breast Cancer
15 Dec 2025 //
BUSINESSWIRE
FDA Launches Probe Into Safety Of Approved Anti-RSV Antibodies
10 Dec 2025 //
BIOSPACE
Therapy Eases Side Effects for 75% of Black Breast Cancer
10 Dec 2025 //
BUSINESSWIRE
DESTINY-Ovarian01—ENHERTU Phase 3 Begins for HER2+Ovarian Cancer
09 Dec 2025 //
BUSINESSWIRE
Merck, Sanofi, AZ Shots For RSV Now Under Scrutiny By FDA
09 Dec 2025 //
FIERCE PHARMA
Pillar Bio, Astrazeneca Expand Liquid Biopsy Access In China
08 Dec 2025 //
PR NEWSWIRE
Neurimmune Expands Collaboration With Astrazeneca On NI009
04 Dec 2025 //
PR NEWSWIRE
AstraZeneca Picks Salesforce Agentforce for Life Sciences
04 Dec 2025 //
BUSINESSWIRE
AstraZeneca`s Record ASH Presence Advances Hematology
04 Dec 2025 //
BUSINESSWIRE
U.S. FDA Accepts Baxdrostat NDA for Priority Review
02 Dec 2025 //
BUSINESSWIRE
Az`s Imfinzi Bags Perioperative Nod In Early-Stage Stomach Cancer
25 Nov 2025 //
FIERCE PHARMA
Harbour Biomed, Astrazeneca Collaborate On Oncology
23 Nov 2025 //
PR NEWSWIRE
AstraZeneca plans $2 Billion Manufacturing Investment
21 Nov 2025 //
PRESS RELEASE
Astrazeneca Strengthens COPD Treatment Pathways
19 Nov 2025 //
EXPRESSPHARMA
Astrazeneca, Sun Pharma Partner To Expand Hyperkalemia Treatment
17 Nov 2025 //
EXPRESSPHARMA
Astrazeneca Lands OPDP Untitled Letter Over Farxiga TV Ad
17 Nov 2025 //
RAPS
Baxdrostat Cuts 24-Hr Systolic BP By 14 mmHg In Bax24 Ph3 Trial
09 Nov 2025 //
BUSINESSWIRE
Regeneron, AZ Regulatory Plans Bolstered By Ph. 3 Wins
07 Nov 2025 //
BUSINESSWIRE
Astrazeneca Expands Obesity Pipeline Focusing On Medical Aspects
06 Nov 2025 //
BIOSPACE
Astrazeneca`s 9M And Q3 2025 Financial Results
06 Nov 2025 //
BUSINESSWIRE
Astrazeneca Adds $136M Investment To Chinese Inhalants Facility
06 Nov 2025 //
FIERCE PHARMA
Breakthrough Properties Finishes Leasing One Helix To Astrazeneca
04 Nov 2025 //
PR NEWSWIRE
EU Okays Alexion’s Koselugo For Adults With Neurofibromatosis
31 Oct 2025 //
INDPHARMAPOST
Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2
30 Oct 2025 //
BUSINESSWIRE
Takeda Drops Az-Partnered Neurological Program After Ph. 2 Fail
30 Oct 2025 //
FIERCE BIOTECH
Biogen Seeks To Stand Out In Lupus With New Anti-CD40L Data
28 Oct 2025 //
BIOSPACE
Novavax offloads HQ lease to AstraZeneca in $60M deal
23 Oct 2025 //
FIERCE PHARMA
Imfinzi Reduces Death Risk By 32% In High-Risk Bladder Cancer
22 Oct 2025 //
INDPHARMAPOST
Novartis Sues Az`s Alexion Over `Misleading` Ultomiris Marketing
22 Oct 2025 //
FIERCE PHARMA
CHMP Recommends Saphnelo Self-Admin Approval For Lupus In EU
21 Oct 2025 //
PHARMIWEB
ESMO: The ADC `Rollercoaster` Rides On With Next-Gen Meds
21 Oct 2025 //
FIERCE BIOTECH
AstraZeneca`s Datroway Extends Survival in Breast Cancer
20 Oct 2025 //
REUTERS
Tezspire Approved for Chronic Rhinosinusitis with Nasal Polyps
20 Oct 2025 //
PRESS RELEASE
AZ Faces FDA Challenge As Imfinzi-Lynparza Miss Survival Goal
19 Oct 2025 //
FIERCE PHARMA
ESMO: Datroway Data Edge Out Trodelvy In First TROP2 Face-Off
19 Oct 2025 //
FIERCE PHARMA
Enhertu+THP Yields 67% pCR in High-Risk HER2+ Breast Cancer
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence or Death Risk by 53% in Ph3 Breast Trial
18 Oct 2025 //
BUSINESSWIRE
ENHERTU® Preceded By THP Yields 67% Pathologic Response
18 Oct 2025 //
BUSINESSWIRE
Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer
18 Oct 2025 //
BUSINESSWIRE
ESMO: Enhertu Wields 2-Fisted Power In Early Breast Cancer
18 Oct 2025 //
FIERCE PHARMA
ESMO: Astrazeneca Data `Validate` Focus On In-House Adcs
18 Oct 2025 //
FIERCE BIOTECH
Imfinzi Cuts Death Risk 22% in Early Gastric Cancer Ph3
17 Oct 2025 //
BUSINESSWIRE
Imfinzi Cuts Recurrence Risk 32% in NMIBC Ph3 POTOMAC
17 Oct 2025 //
BUSINESSWIRE
Datroway`s Rilvegostomig Show Promise Result in Urothelial Cancer
17 Oct 2025 //
BUSINESSWIRE
Az`s Imfinzi Looks Set Up For Another Bladder Cancer Expansion
17 Oct 2025 //
FIERCE PHARMA
Astrazeneca Pens Fresh IBD Collab With Immunai Worth $85M
17 Oct 2025 //
FIERCE BIOTECH
